Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Methylprednisolone blocks autoantibody-induced tissue damage in experimental models of bullous pemphigoid and epidermolysis bullosa acquisita through inhibition of neutrophil activation.

Hellberg L, Samavedam UKSRL, Holdorf K, Hänsel M, Recke A, Beckmann T, Steinhorst K, Boehncke WH, Kirchner T, Möckel N, Solbach W, Zillikens D, Schmidt E, Ludwig RJ, Laskay T.

J Invest Dermatol. 2013 Oct;133(10):2390-2399. doi: 10.1038/jid.2013.91. Epub 2013 Feb 28.

2.

Heat shock protein 90 is required for ex vivo neutrophil-driven autoantibody-induced tissue damage in experimental epidermolysis bullosa acquisita.

Tukaj S, Hellberg L, Ueck C, Hänsel M, Samavedam U, Zillikens D, Ludwig RJ, Laskay T, Kasperkiewicz M.

Exp Dermatol. 2015 Jun;24(6):471-3. doi: 10.1111/exd.12680. Epub 2015 Mar 25.

PMID:
25739426
3.

Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid.

Shimanovich I, Mihai S, Oostingh GJ, Ilenchuk TT, Bröcker EB, Opdenakker G, Zillikens D, Sitaru C.

J Pathol. 2004 Dec;204(5):519-27.

PMID:
15538734
4.

Glucocorticoids in autoimmune bullous diseases: are neutrophils the key cellular target?

Simon D, Borradori L, Simon HU.

J Invest Dermatol. 2013 Oct;133(10):2314-2315. doi: 10.1038/jid.2013.205.

5.

PDE4 Inhibition as Potential Treatment of Epidermolysis Bullosa Acquisita.

Koga H, Recke A, Vidarsson G, Pas HH, Jonkman MF, Hashimoto T, Kasprick A, Ghorbanalipoor S, Tenor H, Zillikens D, Ludwig RJ.

J Invest Dermatol. 2016 Nov;136(11):2211-2220. doi: 10.1016/j.jid.2016.06.619. Epub 2016 Jul 5.

6.

NADPH oxidase is required for neutrophil-dependent autoantibody-induced tissue damage.

Chiriac MT, Roesler J, Sindrilaru A, Scharffetter-Kochanek K, Zillikens D, Sitaru C.

J Pathol. 2007 May;212(1):56-65.

PMID:
17380558
7.

The Leukotriene B4 and its Receptor BLT1 Act as Critical Drivers of Neutrophil Recruitment in Murine Bullous Pemphigoid-Like Epidermolysis Bullosa Acquisita.

Sezin T, Krajewski M, Wutkowski A, Mousavi S, Chakievska L, Bieber K, Ludwig RJ, Dahlke M, Rades D, Schulze FS, Schmidt E, Kalies K, Gupta Y, Schilf P, Ibrahim SM, König P, Schwudke D, Zillikens D, Sadik CD.

J Invest Dermatol. 2017 May;137(5):1104-1113. doi: 10.1016/j.jid.2016.12.021. Epub 2017 Jan 17.

PMID:
28108297
8.

Dimethylfumarate Impairs Neutrophil Functions.

Müller S, Behnen M, Bieber K, Möller S, Hellberg L, Witte M, Hänsel M, Zillikens D, Solbach W, Laskay T, Ludwig RJ.

J Invest Dermatol. 2016 Jan;136(1):117-26. doi: 10.1038/JID.2015.361.

9.

Autoantibodies to bullous pemphigoid and epidermolysis bullosa acquisita antigens in an infant.

Kawachi Y, Ikegami M, Hashimoto T, Matsumura K, Tanaka T, Otsuka F.

Br J Dermatol. 1996 Sep;135(3):443-7.

PMID:
8949441
10.

The Syk Tyrosine Kinase Is Required for Skin Inflammation in an In Vivo Mouse Model of Epidermolysis Bullosa Acquisita.

Németh T, Virtic O, Sitaru C, Mócsai A.

J Invest Dermatol. 2017 Oct;137(10):2131-2139. doi: 10.1016/j.jid.2017.05.017. Epub 2017 May 30.

11.

Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin.

Sitaru C, Schmidt E, Petermann S, Munteanu LS, Bröcker EB, Zillikens D.

J Invest Dermatol. 2002 Apr;118(4):664-71.

12.

The flavonoid luteolin inhibits Fcγ-dependent respiratory burst in granulocytes, but not skin blistering in a new model of pemphigoid in adult mice.

Oswald E, Sesarman A, Franzke CW, Wölfle U, Bruckner-Tuderman L, Jakob T, Martin SF, Sitaru C.

PLoS One. 2012;7(2):e31066. doi: 10.1371/journal.pone.0031066. Epub 2012 Feb 6.

13.

Heat shock protein 90: a pathophysiological factor and novel treatment target in autoimmune bullous skin diseases.

Tukaj S, Zillikens D, Kasperkiewicz M.

Exp Dermatol. 2015 Aug;24(8):567-71. doi: 10.1111/exd.12760. Epub 2015 Jun 3. Review.

PMID:
25980533
14.

Accuracy of indirect immunofluorescence on sodium chloride-split skin in the differential diagnosis of bullous pemphigoid and epidermolysis bullosa acquisita.

Yang B, Wang C, Chen S, Chen X, Zhou G, Tian H, Yu M, Zhang D, Shi Z, Zhang F.

Indian J Dermatol Venereol Leprol. 2011 Nov-Dec;77(6):677-82. doi: 10.4103/0378-6323.86479.

15.

GM-CSF modulates autoantibody production and skin blistering in experimental epidermolysis bullosa acquisita.

Samavedam UK, Iwata H, Müller S, Schulze FS, Recke A, Schmidt E, Zillikens D, Ludwig RJ.

J Immunol. 2014 Jan 15;192(2):559-71. doi: 10.4049/jimmunol.1301556. Epub 2013 Dec 11.

16.

Anti-collagen XVII single-chain Fv antibody blocks the autoimmune reaction mediated by pathogenic autoantibodies in bullous pemphigoid.

Wu Y, Sun NN, Dang EL, Jin L, Liu ZF, Zhang W, Yang LT, Wang G.

J Dermatol Sci. 2013 Oct;72(1):25-31. doi: 10.1016/j.jdermsci.2013.05.010. Epub 2013 Jun 13.

PMID:
23827201
17.

Immobilized immune complexes induce neutrophil extracellular trap release by human neutrophil granulocytes via FcγRIIIB and Mac-1.

Behnen M, Leschczyk C, Möller S, Batel T, Klinger M, Solbach W, Laskay T.

J Immunol. 2014 Aug 15;193(4):1954-65. doi: 10.4049/jimmunol.1400478. Epub 2014 Jul 14.

18.

Fcγ receptors III and IV mediate tissue destruction in a novel adult mouse model of bullous pemphigoid.

Schulze FS, Beckmann T, Nimmerjahn F, Ishiko A, Collin M, Köhl J, Goletz S, Zillikens D, Ludwig R, Schmidt E.

Am J Pathol. 2014 Aug;184(8):2185-96. doi: 10.1016/j.ajpath.2014.05.007.

PMID:
25043618
19.

Recombinant human IgA1 and IgA2 autoantibodies to type VII collagen induce subepidermal blistering ex vivo.

Recke A, Trog LM, Pas HH, Vorobyev A, Abadpour A, Jonkman MF, van Zandbergen G, Kauderer C, Zillikens D, Vidarsson G, Ludwig RJ.

J Immunol. 2014 Aug 15;193(4):1600-8. doi: 10.4049/jimmunol.1400160. Epub 2014 Jul 14.

20.

A patient with both bullous pemphigoid and epidermolysis bullosa acquisita: an example of intermolecular epitope spreading.

Fairley JA, Woodley DT, Chen M, Giudice GJ, Lin MS.

J Am Acad Dermatol. 2004 Jul;51(1):118-22.

PMID:
15243536

Supplemental Content

Support Center